In 2025, it was estimated that there would be over 972 thousand new cancer cases among women in the United States. This statistic illustrates the estimated number of new cancer cases and deaths in the United States for 2025, by gender.

In 2023, there were **** deaths from breast cancer per 100,000 population in the state of South Dakota, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2023, by state.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In the period 2019 to 2023, the death rate for prostate cancer among Hispanic Americans was **** per 100,000 population. This statistic shows the death rate for prostate cancer among U.S. males from 2019 to 2023, by race and ethnicity.

In 2023, Hawaii had the lowest death rate from cancer among all U.S. states, with around 119 deaths per 100,000 population. The states with the highest cancer death rates at that time were Kentucky, West Virginia, and Mississippi. This statistic shows cancer death rates in the United States in 2023, by state.

The graph displays cancer mortality rates by gender in the United States from 1999 to 2023. The x-axis represents the years, labeled from '99 to '23, while the y-axis indicates the mortality rates per 100,000 population for males, females, and the total population. Over this 24-year span, male mortality rates declined from a high of 252.8 in 1999 to a low of 165.4 in 2023. Female mortality rates decreased from 167.2 in 1999 to 123.6 in 2023. The total mortality rate dropped from 200.7 in 1999 to 141.5 in 2023. The data shows a consistent downward trend in cancer mortality rates for both genders and overall. The graph is presented in a line chart format, highlighting the yearly changes and trends in cancer mortality by gender.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

The graph illustrates the number of deaths from cancer in the United States over the period from 1999 to 2023. The x-axis represents the years, labeled with two-digit abbreviations from '99 to '23, while the y-axis displays the annual number of cancer-related deaths. Throughout this 25-year span, the number of deaths ranges from a minimum of 549,829 in 1999 to a maximum of 613,349 in 2023. The data shows a gradual increase in annual deaths over the years. Notably, the number surpassed 550,000 in 2000 with 553,080 deaths, reached 574,738 in 2010, and exceeded 600,000 in 2020 with 602,347 deaths. The figures continued to rise, culminating in the highest recorded number of 613,349 deaths in 2023.

This dataset originates from the American Cancer Societyhttps://cancerstatisticscenter.cancer.org/module/c23c2QoY

According to Cognitive Market Research, the global Cancer Diagnosis market size was USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply with...

In 2023, there were around **** deaths from prostate cancer per 100,000 population in the state of Mississippi, making it the state with the highest prostate cancer death rate that year. This statistic shows the death rate from prostate cancer in the U.S. in 2023, by state.

Snapshot img

Cancer Registry Software Market Size 2025-2029

The cancer registry software market size is valued to increase USD 121.9 million, at a CAGR of 14% from 2024 to 2029. The growing prevalence of cancer cases will drive the cancer registry software market.

Major Market Trends & Insights

North America dominated the market and accounted for a 51% growth during the forecast period.
By End-user - Government and third party segment was valued at USD 24.20 million in 2023
By Type - Stand-alone software segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: 181.04 million
Market Future Opportunities: USD 121.90 million
CAGR : 14%
North America: Largest market in 2023

Market Summary

The market encompasses a continually evolving landscape shaped by advancements in core technologies and applications, service types, and regulatory frameworks. With the growing prevalence of cancer cases worldwide, the demand for robust and efficient cancer registry software solutions has surged. The growth is fueled by the increasing clinical research for oncology and the need for accurate, standardized data collection and analysis.
However, data privacy and security concerns pose significant challenges, necessitating stringent compliance with regulations such as HIPAA and GDPR. As regional healthcare systems adopt digital transformation, the market is witnessing a proliferation of solutions tailored to specific needs in North America, Europe, and Asia Pacific.

What will be the Size of the Cancer Registry Software Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Registry Software Market Segmented and what are the key trends of market segmentation?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premises
  Cloud-based


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period.

Cancer registry software plays a pivotal role in assisting government and third-party agencies in managing and analyzing data related to cancer cases. These solutions facilitate the collection, storage, and statistical modeling of oncology data, enabling agencies to monitor cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. Governments utilize cancer registry software to ensure data quality through data validation rules, de-identification, and HIPAA compliance. They also employ data visualization tools, reporting dashboards, and data integration methods to analyze trends and patterns. This data analysis helps identify high-risk populations, geographic disparities, and emerging cancer types.

Moreover, cancer registry software supports population health management and patient data management, ensuring secure data storage, user access control, and audit trails. API integrations enable seamless data exchange with other healthcare systems, facilitating clinical data exchange and follow-up procedures. The future of cancer registry software is promising, with adoption expected to grow significantly. According to recent studies, the number of cancer registries worldwide is projected to increase by 20%, while the use of electronic registries is anticipated to surge by 30%. These trends reflect the ongoing digitization of healthcare and the growing recognition of the value of data-driven insights in improving cancer care and outcomes.

Request Free Sample

The Government and third party segment was valued at USD 24.20 million in 2019 and showed a gradual increase during the forecast period.

Furthermore, cancer registry software supports cancer surveillance, disease registries, and cancer staging, providing valuable data for mortality reporting and treatment protocols. It also facilitates incidence reporting, case ascertainment, and survival analysis, ensuring that governments and third-party agencies have access to the most accurate and up-to-date information for informed decision-making. In conclusion, cancer registry software is a crucial tool for governments and third-party agencies seeking to monitor and improve cancer care. Its features, including

The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2023, the death rate from breast cancer was **** per 100,000 population. However, cancer is a serious public health issue in the United States and is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women have the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

Introduction

Global AI in Cancer Diagnosis Market is growing rapidly. It is expected to reach USD 1943.6 million by 2033, up from USD 175.3 million in 2023. This represents a compound annual growth rate (CAGR) of 27.2% from 2024 to 2033. With a market share over 58.4%, North America held a strong lead in 2023, reaching USD 102.3 Million in revenue.

This expansion highlights the pivotal role of artificial intelligence (AI) in transforming cancer diagnostics, driven by the growing incidence of cancer and the urgent need for precise and efficient diagnostic methods.

Key drivers of this market growth include the escalating global cancer rates, which demand advanced solutions for early detection and accurate diagnosis. North America is anticipated to maintain its market dominance, due to its high cancer incidence and the substantial adoption of AI technologies in healthcare diagnostics. AI integration significantly boosts the accuracy, speed, and efficiency of cancer diagnosis, enabling timely treatment decisions and personalized care.

Recent developments in the sector emphasize its dynamic nature and potential for innovation. Strategic partnerships between leading healthcare providers and technology companies are enhancing AI-driven diagnostic tools, which help clinicians deliver more effective care. These collaborations are crucial for developing and refining AI applications that aim to improve diagnostic precision, minimize delays, and ultimately enhance patient outcomes.

However, the market faces challenges such as the need for extensive data sets to train AI algorithms, high integration costs, and complex regulatory environments. Despite these obstacles, ongoing advancements in AI technology and an increased focus on personalized medicine are expected to promote the widespread adoption of AI in cancer diagnosis. This signifies a promising new phase of innovation and improved care within the oncology sector.

The AI in cancer diagnosis market stands at a critical point, with significant growth opportunities and the potential to profoundly impact healthcare delivery. Marked by technological progress, strategic alliances, and a dedicated focus on enhancing diagnostic processes, the sector is poised to contribute to better patient outcomes and more efficient healthcare systems.

US Cancer Biomarkers Market size was valued at USD 4.04 Billion in the year 2023 and it is expected to reach USD 7.48 Billion in 2031, at a CAGR of 9.2% over the forecast period of 2024 to 2031.

Rising Prevalence of Cancer: The increasing cancer burden in the United States continues to drive biomarker market growth, with approximately 1.9 million new cancer cases diagnosed in 2023. The American Cancer Society projects a 45% increase in cancer cases from 2015 to 2030, with one in three Americans developing cancer in their lifetime. This substantial disease burden has led to a $15.2 billion market value for cancer biomarker testing in 2023, growing at a CAGR of 12.8% through 2028.

Advancements in Technology: The evolution of biomarker testing technologies has dramatically improved cancer diagnostics and monitoring. The cost of genome sequencing has plummeted from $100 million in 2001 to under $1,000 in 2023, making testing more accessible. Currently, 85% of major cancer centers utilize NGS-based biomarker testing, while advanced imaging technologies and molecular diagnostics have achieved a 95% accuracy rate in certain cancer types. The integration of AI and machine learning has further enhanced biomarker detection efficiency by 40%.

Shift Toward Personalized Medicine: Personalized medicine adoption has surged, with 73% of oncologists regularly using biomarker testing for treatment decisions. Targeted therapies based on biomarker testing show 30-40% higher success rates compared to traditional treatments. The FDA approved over 25 new biomarker-based cancer therapies in 2023, while 30-40% of all cancer treatments now involve biomarker testing to determine patient-specific approaches.

According to Cognitive Market Research , the global Targeted Cancer Drugs Market size will be XX million by 2033, whereas its compound annual growth rate (CAGR) will be XX% from 2025 to 2033. • North America held the largest share of the global Targeted Cancer Drugs market around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Asia Pacific held a market share of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Europe accounted for a share of over XX% of the global market size of USD XX million. • The Latin American market is around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. Market Dynamics of the Targeted Cancer Drugs Market

Key Drivers of the Targeted Cancer Drugs Market

Rising incidence of cancer enhances the targeted cancer drugs market growth

Tobacco use, high body mass index, alcohol usage, low intake of fruits and vegetables, and lack of physical activity are responsible for about one-third of cancer-related risk. Furthermore, one significant risk factor for lung cancer is air pollution. About 30% of cancer cases in low- and lower-middle-income nations are caused by diseases that cause cancer, such as hepatitis and the human papillomavirus (HPV). How frequently a cancer arises (incidence) and how long people typically live after being diagnosed (survival) are the two factors that determine cancer prevalence. This indicates that the most prevalent malignancies with the longest survival have the highest prevalence counts. Compared to a less common cancer with a longer survival, a common cancer with a shorter survival may have a lower prevalence count. For instance, according to the American Cancer Society 2023, non-Hodgkin lymphoma, a less common cancer, has a higher prevalence rate than lung cancer, despite lung cancer being one of the most common malignancies in the US. There are more persons living after a diagnosis of non-Hodgkin lymphoma than after a diagnostic of lung cancer because those with non-Hodgkin lymphoma have a higher chance of surviving longer than those with lung cancer. There were 1,777,566 new cases of cancer reported in the US in 2021. An estimated 608,366 Americans lost their lives to cancer in 2022. https://www.cdc.gov/cancer/data/index.html In the twenty-first century, cancer is a significant social, public health, and economic issue, accounting for about one in six fatalities (16.8%) and one in four deaths (22.8%) from noncommunicable diseases (NCDs) globally. Three out of ten premature deaths worldwide are caused by NCDs (30.3% in people aged 30 to 69), and in 177 out of 183 nations, it ranks among the top three causes of death for this age group. Apart from being a significant hindrance to extending life expectancy, cancer is linked to significant societal and macroeconomic expenses, which differ in extent depending on the type of cancer, location, and gender. For instance, according to International Agency for Research on Cancer in 2022, there were about 20 million new cases of cancer, including nonmelanoma skin cancers (NMSCs), and 9.7 million cancer-related deaths. According to estimates, one in five men and women will get cancer at some point in their lives, while one in nine men and one in twelve women will pass away from the disease. With about 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers), lung cancer was the most commonly diagnosed cancer in 2022. It was followed by stomach (4.9%), colorectum (9.6%), prostate (7.3%), and female breast (11.6%) cancers. With an anticipated 1.8 million deaths (18.7%), lung cancer was also the most common cause of cancer-related mortality. Colorectal (9.3%), liver (7.8%), female breast (6.9%), and stomach (6.8%) cancers were next in line. The two most common cancers in both men and women were lung and breast cancer. https://acsjournals.onlinelibrary.wile...

Hypopharyngeal Cancer Treatment Market Outlook

The hypopharyngeal cancer treatment market size was valued at USD 1.2 billion in 2023 and is expected to reach USD 2.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.5%. The significant growth factor driving this market includes advancements in treatment methods and increasing incidence rates of head and neck cancers. The emergence of personalized medicine and targeted therapies, alongside growing investments in healthcare infrastructure, are propelling the market forward.

One of the primary growth factors for the hypopharyngeal cancer treatment market is the rising incidence of head and neck cancers globally. According to the World Health Organization (WHO), head and neck cancers account for more than 550,000 cases annually. Hypopharyngeal cancer, although less common, contributes significantly to this figure. The aging population, coupled with lifestyle factors such as tobacco and alcohol consumption, contributes to the increasing diagnosis rates. Furthermore, enhanced awareness about early cancer detection and regular screenings are also playing a crucial role in identifying and treating hypopharyngeal cancer at earlier stages, thereby driving market growth.

Another critical growth driver is the advancements in medical technology and treatment options. The development of cutting-edge therapies such as targeted therapy and immunotherapy offers new hope for more effective treatments with fewer side effects compared to traditional methods like chemotherapy and radiation therapy. Companies and research institutions are investing heavily in R&D to discover innovative treatment modalities. This influx of advanced treatment options not only improves patient outcomes but also broadens the market scope, attracting more patients to seek medical intervention.

Moreover, the increasing healthcare expenditure and supportive government initiatives in various regions are bolstering the market expansion. Developed regions like North America and Europe are witnessing substantial investments in healthcare infrastructure, making advanced treatments accessible to a larger patient base. Emerging economies in the Asia Pacific and Latin America are also focusing on improving their healthcare systems, supported by favorable government policies and international collaborations. This global effort to enhance cancer care is significantly contributing to the growth of the hypopharyngeal cancer treatment market.

Regionally, North America holds a prominent position in the hypopharyngeal cancer treatment market. This can be attributed to the advanced healthcare infrastructure, high awareness levels, and significant investments in cancer research. Europe follows closely, driven by similar factors. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing healthcare investments and rising cancer incidence rates. Countries like China and India are focusing on enhancing their healthcare services, which is anticipated to drive market growth in this region. Latin America and the Middle East & Africa are also showing promising growth, though at a comparatively slower pace due to varying degrees of healthcare infrastructure development.

Treatment Type Analysis

The treatment type segment is a pivotal component of the hypopharyngeal cancer treatment market, encompassing surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. Surgery remains a cornerstone in the treatment of hypopharyngeal cancer, often used in combination with other therapies for comprehensive management. Advanced surgical techniques, such as minimally invasive procedures and robotic-assisted surgeries, are enhancing precision and outcomes, thus propelling the growth of this segment. The increasing adoption of these advanced procedures is expected to continue driving market growth.

Radiation therapy is another critical segment, often employed as both a primary treatment and an adjuvant to surgery and chemotherapy. Technological advancements in radiation therapy, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT), offer targeted treatment options with minimized damage to surrounding tissues. These innovations are significantly enhancing the efficacy of radiation therapy, making it a preferred choice for many patients and healthcare providers. The growing availability of

Snapshot img

Cancer Diagnostics Market Size 2024-2028

The cancer diagnostics market size is valued to increase USD 17.74 billion, at a CAGR of 13.64% from 2023 to 2028. High prevalence of cancer will drive the cancer diagnostics market.

Major Market Trends & Insights

North America dominated the market and accounted for a 44% growth during the forecast period.
By End-user - Hospitals and clinics segment was valued at USD 6.71 billion in 2022
By Type - IVD segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 220.16 million
Market Future Opportunities: USD 17744.50 million
CAGR : 13.64%
North America: Largest market in 2022

Market Summary

The market represents a significant and continually evolving sector, driven by the high prevalence of cancer worldwide. According to the World Health Organization, an estimated 19.3 million new cancer cases and nearly 10.0 million cancer deaths occurred in 2020. Core technologies, such as molecular diagnostics and imaging, are at the forefront of innovation, enabling earlier and more accurate detection. Applications, including liquid biopsies and non-invasive tests, are gaining traction due to their convenience and potential for improved patient outcomes. Service types, including laboratory testing and in-vitro diagnostics, are essential components of the market, with increasing investment in research and development (R&D) and advances in technology.
Despite these opportunities, challenges persist, including the high cost of developing companion diagnostics and navigating complex regulatory landscapes. The market's dynamics are shaped by these factors and the ongoing unfolding of regional trends, with North America and Europe leading in market share due to advanced healthcare infrastructure and robust R&D investments.

What will be the Size of the Cancer Diagnostics Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Cancer Diagnostics Market Segmented and what are the key trends of market segmentation?

The cancer diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals and clinics
  Diagnostic laboratories


Type

  IVD
  Imaging
  LDT


Geography

  North America

    US
    Canada


  Europe

    France
    Germany


  APAC

    China


  Rest of World (ROW)

By End-user Insights

The hospitals and clinics segment is estimated to witness significant growth during the forecast period.

The market holds significant importance in the healthcare sector, delivering essential benefits to hospitals and clinics. This market's impact is felt across various levels, including enhanced patient care and satisfaction, operational efficiency at POC (Point of Care), and cost savings through strengthened operational bottom lines. In 2023, hospitals emerged as the primary revenue drivers for the market expansion. This growth can be attributed to the rising prevalence of chronic diseases, such as cervical, head and neck, lung, skin, and colorectal cancers, and the availability of skilled professionals adept at utilizing advanced diagnostic tools. These tools include circulating tumor cells analysis, cytogenetic analysis, molecular profiling, and liquid biopsy, among others.

Request Free Sample

The Hospitals and clinics segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.

Furthermore, the ongoing pursuit of biomarker discovery, minimal residual disease detection, and personalized medicine initiatives fuel market growth. Multiplex assays, RNA sequencing, and gene expression analysis are integral to these advancements. Prognostic markers, protein biomarkers, and predictive biomarkers are crucial in therapeutic response assessment and treatment efficacy evaluation. Clinical validation, early detection, and disease progression monitoring are integral to market development. Technologies like microarray technology, DNA sequencing, next-generation sequencing, mass spectrometry, and digital pathology are continually evolving to enhance diagnostic accuracy and reduce false negative and false positive rates. Diagnostic imaging and cancer screening are also integral components of the market, ensuring optimal patient care and outcomes.

The market's future growth is expected to be driven by the increasing adoption of targeted therapies and regulatory approvals for innovative diagnostic solutions.

Request Free Sample

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional t

Overview

New York, NY – Sep 02, 2025: The global radiotherapy market is projected to reach USD 12.1 billion by 2033, increasing from USD 6.8 billion in 2023, with a CAGR of 5.9% during 2023–2032. Radiotherapy remains an essential cancer treatment, used in more than half of cancer cases worldwide, either alone or in combination with surgery and chemotherapy. The growing burden of cancer, highlighted by the World Health Organization as a leading cause of morbidity and mortality, significantly drives market demand. Rising cancer incidence, coupled with increasing patient survival rates due to effective radiotherapy, continues to strengthen the industry outlook.

Technological progress is reshaping treatment methods and improving precision. Innovations such as Intensity-Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), Stereotactic Body Radiotherapy (SBRT), and Proton Beam Therapy minimize damage to healthy tissues and improve patient outcomes. Hospitals and cancer centers are heavily investing in these advanced systems, accelerating adoption. In parallel, the integration of artificial intelligence (AI) is streamlining radiotherapy planning and automation. AI-driven solutions reduce errors, enable personalized therapies, and improve efficiency, ensuring faster treatment cycles for patients.

Healthcare expenditure is also fueling growth. Governments and private institutions in both developed and emerging markets are allocating significant budgets for oncology care infrastructure. The installation of advanced radiotherapy equipment is supported by favorable reimbursement policies in several regions. These frameworks reduce out-of-pocket expenses for patients, increasing accessibility and encouraging widespread adoption of radiotherapy services. This trend is reinforced by a global shift toward outpatient and non-invasive procedures, offering quicker recovery and higher patient acceptance.

Demographic trends further support market expansion. The aging global population, with an increasing share of individuals above 60 years, faces higher cancer risk. This demographic shift is a major driver of radiotherapy demand. Emerging economies, including India, China, and Brazil, are playing a critical role by investing in cancer care infrastructure. Awareness campaigns, expanding healthcare coverage, and government-backed initiatives in these regions are boosting the availability and utilization of radiotherapy treatments.

Strategic collaborations and investments strengthen innovation within the sector. Partnerships among hospitals, research institutions, and medical technology firms drive advancements in radiotherapy techniques. Significant funding from both public and private sectors supports the development and commercialization of next-generation technologies. These combined forces—rising cancer prevalence, technological advancements, healthcare investments, and global collaborations—are expected to sustain steady growth in the global radiotherapy market throughout the forecast period.

The leading causes of death among Black residents in the United States in 2023 included diseases of the heart, cancer, unintentional injuries, and stroke. The leading causes of death for African Americans generally reflect the leading causes of death for the entire United States population. However, a major exception is that death from assault or homicide is the seventh leading cause of death among African Americans but is not among the ten leading causes for the general population. Homicide among African Americans The homicide rate among African Americans has been higher than that of other races and ethnicities for many years. In 2023, around 9,284 Black people were murdered in the United States, compared to 7,289 white people. A majority of these homicides are committed with firearms, which are easily accessible in the United States. In 2023, around 13,350 Black people died by firearms. Cancer disparities There are also major disparities in access to health care and the impact of various diseases. For example, the incidence rate of cancer among African American males is the greatest among all ethnicities and races. Furthermore, although the incidence rate of cancer is lower among African American women than it is among white women, cancer death rates are still higher among African American women.